|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |
| --- | --- | --- |
|

|  |
| --- |
| **NIBRT is pleased to announce the appointment of PM Group to develop a design to expand its existing facility.** |

|  |
| --- |
|  |

 |

|  |  |  |
| --- | --- | --- |
|

|  |
| --- |
|  |

|  |
| --- |
|  |

 |

|  |  |
| --- | --- |
|

|  |
| --- |
|  |

 |

 |

 |
|

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|

|  |  |  |  |
| --- | --- | --- | --- |
|

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
|  |

 |

 |

 |

 |

 |
|

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| **The National Institute for Bioprocessing Research and Training (NIBRT) is pleased to announce the appointment of PM Group to develop a design to expand its existing facility. The expansion project will facilitate the training, research and innovation for the manufacture of Cell and Gene Therapy (CGT) medicines.****DUBLIN, IRELAND, February 19th 2020**The commercial value of Cell and Gene Therapies (CGTs) is forecasted to grow exponentially over coming years to a very substantial $10 billion-30 billion for 2025 with a with CAGR of 105% between 2019-2025. As new pathways for disease treatment and cure command growing attention and investment, the total number of next generation biologics (the majority of which are CGTs) in the development pipeline reached 269 by the end of 2018, up from 120 in 2015.Ireland has established a hard won reputation as a centre of excellence in biopharma manufacturing mainly focused on monoclonal antibodies. However, the new wave of biopharma investments will include next generation biologics (mainly CGTs) which represent complex challenges to manufacture economically. NIBRT and its partners established a CGT Forum in December 2018 to address these challenges, publishing a White Paper in May 2019, announced several CGT research collaborations and commenced CGT training activity in Q4 2019.To further facilitate CGT training and research, NIBRT has appointed PM Group to develop a design to expand NIBRT’s existing facility in Dublin, Ireland.   With this expansion NIBRT will be able to support the workforce development and research expertise that underpins global CGT manufacturing investments.“*PM Group is delighted to be appointed to work on the concept design of NIBRT’s new CGT training facility.  It is an exciting next step and builds on our track record of innovation in the CGT space and our partnership with NIBRT*,” said Eileen Lee, Dublin Office Operations Manager, PM GroupAnnouncing the appointment of PM Group NIBRT CEO, Dominic Carolan stated *“We are delighted to partner with the PM Group, who are renowned leading experts in the provision of facilities for CGT manufacturing. This design will position NIBRT to train our industry and educational clients in the current and emergent CGT manufacturing technologies as well as continuing expansion of our CGT research activities* *”* Further information on NIBRT’s CGT training programmes are available [here.](https://www.nibrt.ie/training-and-education/training-courses/) [[1]](https://us13.admin.mailchimp.com/campaigns/preview-content-html?id=192485" \l "_ftnref1" \o ") IQVIA White Paper (2018): Changing the game – Cell and gene therapies lead the Advanced Therapies revolution*Pictured: (left to right), Dominic Carolan ( NIBRT, CEO), Eileen Lee ( PM Group, Process Group Manager)*   |

 |

|  |  |
| --- | --- |
|

|  |
| --- |
| **About NIBRT**The National Institute for Bioprocessing Research and Training (NIBRT) is a global centre of excellence for training and research in biopharmaceutical manufacturing. NIBRT is located in a world class facility in Dublin, Ireland. This facility is purpose built to closely replicate a modern bioprocessing plant with state-of-the-art equipment and enables NIBRT to offer the highest quality training and research solutions. NIBRT’s mission is to support the growth and development of all aspects of the biopharmaceutical manufacturing industry.For more information go to [www.nibrt.ie](http://www.nibrt.ie/) |

 |

|  |  |
| --- | --- |
|

|  |
| --- |
|  **About PM Group**Headquartered in Ireland, PM Group is an employee owned, international project delivery company, with operations across Europe, the USA and Asia. The Group has a 47 year track record in project management, process design, facility design and construction management for leading multinational companies. It is a leader in the Pharma, Food, Mission Critical, Med-Tech and Advanced Manufacturing sectors.  |

 |

|  |  |
| --- | --- |
|

|  |
| --- |
| **For more information, please contact:**NIBRT Media ContactAlison QuinnMarketing and Communications ManagerNational Institute for Bioprocessing Research and TrainingT: +353 1 215 8194alison.quinn@nibrt.iePM Group Media ContactAnna KilpatrickDrury PNT: +353 87 692 9458anna.kilpatrick@drurypn.ie |

 |

 |

 |